<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract In December 2019, a novel severe" exact="acute" post="respiratory syndrome (SARS) from a new coronavirus (SARS-CoV-2) was"/>
 <result pre="license (http://creativecommons.org/licenses/by/4.0/). Abstract In December 2019, a novel severe acute" exact="respiratory" post="syndrome (SARS) from a new coronavirus (SARS-CoV-2) was recognized"/>
 <result pre="(http://creativecommons.org/licenses/by/4.0/). Abstract In December 2019, a novel severe acute respiratory" exact="syndrome" post="(SARS) from a new coronavirus (SARS-CoV-2) was recognized in"/>
 <result pre="the world reaching pandemic proportions. High mortality rates characterize SARS-CoV-2" exact="disease" post="(COVID-19), which mainly affects the elderly, causing unrestrained cytokines-storm"/>
 <result pre="which mainly affects the elderly, causing unrestrained cytokines-storm and subsequent" exact="pulmonary" post="shutdown, also suspected micro thromboembolism events. At the present"/>
 <result pre="females, with males 65% more likely to die from the" exact="infection" post="than females. Data from the World Health Organization (WHO)"/>
 <result pre="Kong hospitals state that 32% of male and 15% of" exact="female" post="COVID-19 patients required intensive care or died. On the"/>
 <result pre="ACE2 RAS-pathway TMPRSS2 sex/gender-gap lung shut-down prognostic molecular/genetic markers inflammation" exact="thrombosis" post="1. Introduction SARS-CoV-2 belongs to the Î²-coronavirus family and"/>
 <result pre="SARS-CoV-2 belongs to the Î²-coronavirus family and the associated severe" exact="acute" post="respiratory syndrome (SARS), like the previous SARS-CoV and Middle"/>
 <result pre="belongs to the Î²-coronavirus family and the associated severe acute" exact="respiratory" post="syndrome (SARS), like the previous SARS-CoV and Middle East"/>
 <result pre="to the Î²-coronavirus family and the associated severe acute respiratory" exact="syndrome" post="(SARS), like the previous SARS-CoV and Middle East respiratory"/>
 <result pre="respiratory syndrome (SARS), like the previous SARS-CoV and Middle East" exact="respiratory" post="syndrome (MERS-CoV), it may cause life-threatening diseases [1,2,3,4,5,6]. Data"/>
 <result pre="syndrome (SARS), like the previous SARS-CoV and Middle East respiratory" exact="syndrome" post="(MERS-CoV), it may cause life-threatening diseases [1,2,3,4,5,6]. Data from"/>
 <result pre="match with emerging observations, indicating a large, sex-dependent gap in" exact="disease" post="infection and outcomes for SARS-CoV-2 disease (COVID-19) as for"/>
 <result pre="with emerging observations, indicating a large, sex-dependent gap in disease" exact="infection" post="and outcomes for SARS-CoV-2 disease (COVID-19) as for previous"/>
 <result pre="large, sex-dependent gap in disease infection and outcomes for SARS-CoV-2" exact="disease" post="(COVID-19) as for previous SARS [7,8]. Moreover, people aged"/>
 <result pre="cytokines-storm in the early phase of the illness [11,12]. Accordingly," exact="thrombosis" post="due to coagulation unbalance or inherited or acquired thrombophilia"/>
 <result pre="[11,12]. Accordingly, thrombosis due to coagulation unbalance or inherited or" exact="acquired" post="thrombophilia is a rare event among children [13,14,15,16,17], and"/>
 <result pre="Accordingly, thrombosis due to coagulation unbalance or inherited or acquired" exact="thrombophilia" post="is a rare event among children [13,14,15,16,17], and this"/>
 <result pre="found in the elderly severest cases as well the rarer" exact="disseminated intravascular coagulation" post="(DIC) [18,19,20], strongly substantiating heparin-based anticoagulant treatments in the"/>
 <result pre="[23,24,25,26]. Accordingly, in a mouse model, gonadectomy did not affect" exact="disease" post="outcome in male mice, whilst ovariectomy or estrogen receptor"/>
 <result pre="estrogen receptor antagonists caused increased mortality in females after SARS-CoV" exact="infection" post="[7]. This observation also strongly agrees with the fact"/>
 <result pre="adaptive immune responses and are relatively more resistant to virus" exact="infections" post="than males. The difference in the copy number of"/>
 <result pre="infections than males. The difference in the copy number of" exact="X-linked" post="genes involved in the immune response and the presence"/>
 <result pre="the immune response and the presence of genes dedicated to" exact="disease" post="susceptibility in males and females may account for any"/>
 <result pre="have immune-suppressive effect at higher levels and immune-stimulant activity at" exact="lower" post="levels [27,31,32,33], with peculiar functions to contrast virus replication"/>
 <result pre="to contrast virus replication in selected tissues such as nasal" exact="epithelial" post="cells in humans [34]. Less investigated, is whether differences"/>
 <result pre="has been described how a modest ACE2 expression characterizes the" exact="upper" post="human respiratory tract and that this should limit the"/>
 <result pre="described how a modest ACE2 expression characterizes the upper human" exact="respiratory" post="tract and that this should limit the receptivity of"/>
 <result pre="virus entry and/or exclusively contribute to ACE1/ACE2 unbalancing, inflammation and" exact="thrombosis" post="[40]. Furthermore, estrogens increase ADAM17 and ADAM10 expression levels,"/>
 <result pre="two putative shedders also responsible for many ectodomain cleavages in" exact="atherosclerosis" post="[41], suggesting their protective role against cardiovascular events in"/>
 <result pre="ectodomain cleavages in atherosclerosis [41], suggesting their protective role against" exact="cardiovascular" post="events in females, a mechanism potentially accounting for the"/>
 <result pre="and interaction is a key determinant for the success of" exact="viral infection" post="and receptivity [35]. Recently, the S-protein/ACE2 interface has been"/>
 <result pre="interaction is a key determinant for the success of viral" exact="infection" post="and receptivity [35]. Recently, the S-protein/ACE2 interface has been"/>
 <result pre="functionality is essential for both virus cell entry and local" exact="pulmonary" post="homeostasis, and although it has been previously described that"/>
 <result pre="(ACE2/Ang1-7/MAS-axis) actions. This results in the protection of organs and" exact="blood vessels" post="by anticoagulant, anti-inflammatory, anti-proliferation, anti-fibrosis, anti-alveolar epithelial cell apoptosis,"/>
 <result pre="organs and blood vessels by anticoagulant, anti-inflammatory, anti-proliferation, anti-fibrosis, anti-alveolar" exact="epithelial" post="cell apoptosis, and anti-oxidative stress activities antagonizing the Ang-II"/>
 <result pre="and apoptosis in the alveolar cells, accelerating lung damage and" exact="pulmonary" post="shut-down triggered/worsened by the SARS-CoV-2 infection. Most likely, it"/>
 <result pre="the multistep pathogenesis and the age/sex-gaps of such a complex" exact="infection" post="and progression, considering also that ACE2 (locus Xp22.2) and"/>
 <result pre="progression, considering also that ACE2 (locus Xp22.2) and Ang-II receptor" exact="type 2" post="gene (AGTR2, alias AT2, locus Xq23) are both located"/>
 <result pre="AT2, locus Xq23) are both located on the X-chromosome. Essentially," exact="X-linked" post="heterozygous alleles could activate in females a mosaic advantage"/>
 <result pre="mosaic advantage and a greater sexual dimorphism that might counteract" exact="viral infection," post="local inflammation due to cytokine storms and severe outcomes."/>
 <result pre="COVID-19 also in the general population. 2. ACE1/ACE2 Pathway and" exact="Acute" post="Respiratory Distress Syndrome (ARDS) The reninâ€&quot;angiotensin system (RAS) acts"/>
 <result pre="also in the general population. 2. ACE1/ACE2 Pathway and Acute" exact="Respiratory" post="Distress Syndrome (ARDS) The reninâ€&quot;angiotensin system (RAS) acts as"/>
 <result pre="the general population. 2. ACE1/ACE2 Pathway and Acute Respiratory Distress" exact="Syndrome" post="(ARDS) The reninâ€&quot;angiotensin system (RAS) acts as a homeostatic"/>
 <result pre="reninâ€&quot;angiotensin system (RAS) acts as a homeostatic regulator of the" exact="vascular" post="function, including blood pressure and volume control, starting with"/>
 <result pre="local tissue homeostasis by anti-inflammatory, anti-coagulant, anti-proliferation, anti-fibrosis, anti-apoptosis of" exact="epithelial" post="cells, and anti-oxidative stress activities, also controlling the local"/>
 <result pre="Moreover, a high ACE2/ACE1 ratio protects against endothelial dysfunctions and" exact="vascular" post="pathologies, exogenous ACE2 activation promotes antithrombotic activity, and the"/>
 <result pre="heart, intestine, and kidney and, as recently demonstrated, on the" exact="epithelial" post="cells of oral mucosa and the tongue [36], sharing"/>
 <result pre="and, as recently demonstrated, on the epithelial cells of oral" exact="mucosa" post="and the tongue [36], sharing both tissue expression sites"/>
 <result pre="of several complex pathological conditions such as hypertension, atherosclerosis, thrombosis," exact="heart" post="or kidney failure, and severe acute respiratory distress [48]."/>
 <result pre="complex pathological conditions such as hypertension, atherosclerosis, thrombosis, heart or" exact="kidney failure," post="and severe acute respiratory distress [48]. In the lung,"/>
 <result pre="as hypertension, atherosclerosis, thrombosis, heart or kidney failure, and severe" exact="acute" post="respiratory distress [48]. In the lung, ACE1 is highly"/>
 <result pre="hypertension, atherosclerosis, thrombosis, heart or kidney failure, and severe acute" exact="respiratory" post="distress [48]. In the lung, ACE1 is highly expressed,"/>
 <result pre="ACE2 is mainly clustered in type-II alveolar cells [36,55,56,57]. During" exact="acute" post="respiratory distress syndrome (ARDS), a local RAS unbalance cannot"/>
 <result pre="is mainly clustered in type-II alveolar cells [36,55,56,57]. During acute" exact="respiratory" post="distress syndrome (ARDS), a local RAS unbalance cannot maintain"/>
 <result pre="clustered in type-II alveolar cells [36,55,56,57]. During acute respiratory distress" exact="syndrome" post="(ARDS), a local RAS unbalance cannot maintain appropriate oxygenation,"/>
 <result pre="a local RAS unbalance cannot maintain appropriate oxygenation, thus inducing" exact="pulmonary" post="edema, inflammation, and hyper-proliferation, establishing in turn severe pulmonary"/>
 <result pre="inducing pulmonary edema, inflammation, and hyper-proliferation, establishing in turn severe" exact="pulmonary" post="shutdown [48,52,58]. The observations from the previous SARS epidemic"/>
 <result pre="binding of the spike protein to the host cell, inhibiting" exact="infection" post="rate and mortality, are a valuable rationale to start"/>
 <result pre="[63], whereas ACE2 deficient mice result in renal injury and" exact="glomerulosclerosis" post="[64,65]. These alterations are reversed or ameliorated by treatment"/>
 <result pre="a modulation of ACE1 activity may be helpful to avoid" exact="pulmonary" post="disease progression (Figure 2) [37,58,71,72,73,74]. Accordingly, several international societies"/>
 <result pre="modulation of ACE1 activity may be helpful to avoid pulmonary" exact="disease" post="progression (Figure 2) [37,58,71,72,73,74]. Accordingly, several international societies recommend"/>
 <result pre="recommend not to stop treatments with RAS pathway antagonists in" exact="cardiovascular disease" post="patients [40], and a recent editorial comments on several"/>
 <result pre="not to stop treatments with RAS pathway antagonists in cardiovascular" exact="disease" post="patients [40], and a recent editorial comments on several"/>
 <result pre="having the highest serum/tissue ACE1 levels, the I/D genotype showing" exact="intermediate" post="levels, and the I/I genotype the lowest levels [81]."/>
 <result pre="can be considered a genetic predisposition affecting the progression from" exact="pneumonia" post="to SARS, as reported in a study with Vietnamese"/>
 <result pre="is a significant sex-difference in serum ACE1 activity/level, which is" exact="lower" post="among females in both healthy and pathological conditions [81,87,88,89]."/>
 <result pre="during ACE2 receptor suppression, as in the presence of SARS-CoV-2" exact="infection" post="[35,37]. Interestingly, a quantitative variation in ACE1 levels has"/>
 <result pre="and epidemic rate reduction. This ascribed to O-blood group a" exact="lower" post="risk of infection, hypothesizing that natural anti-A and anti-B"/>
 <result pre="natural anti-A and anti-B antibodies can contribute in protecting against" exact="viral" post="diseases at the population level [93]. The ACE2 gene"/>
 <result pre="issues remain almost inconclusive [95,96]. Unlike autosomal genes (i.e., ACE1)," exact="X-linked" post="genes (i.e., ACE2) cannot show in males any advantageous"/>
 <result pre="or polymorphic at-risk conditions. Accordingly, in the presence of a" exact="lower" post="activity of the ACE2 gene, as for the one"/>
 <result pre="activity (i.e., GG-females or hemizygous G-males) could account for increased" exact="susceptibility to" post="hypertension mainly in association with classical cardiovascular risk factors"/>
 <result pre="GG-females or hemizygous G-males) could account for increased susceptibility to" exact="hypertension" post="mainly in association with classical cardiovascular risk factors such"/>
 <result pre="for increased susceptibility to hypertension mainly in association with classical" exact="cardiovascular" post="risk factors such as old age, dyslipidemia, and diabetes"/>
 <result pre="classical cardiovascular risk factors such as old age, dyslipidemia, and" exact="diabetes" post="[97]. Noticeably, it emerges that an overly activated RAS,"/>
 <result pre="ACE1/ACE2 balance and in combination with advanced age and classic" exact="acquired" post="cardiovascular risk conditions, might lead to systemic disorders and/or"/>
 <result pre="balance and in combination with advanced age and classic acquired" exact="cardiovascular" post="risk conditions, might lead to systemic disorders and/or severe"/>
 <result pre="age and classic acquired cardiovascular risk conditions, might lead to" exact="systemic" post="disorders and/or severe local disturbances of the normal tissue"/>
 <result pre="the S-protein, which is critical to the success of the" exact="viral infection." post="The affinity between ACE2 and the RBD of the"/>
 <result pre="network of polar interactions between amino acid residues ensures a" exact="stable" post="and functional dimer assembly. Several gene polymorphisms have been"/>
 <result pre="suggested to be crucial for dimer stability in the PD" exact="and neck" post="domains of the ACE2 gene [106,107]. Theoretically, this might"/>
 <result pre="by chloroquine treatment of SARS-CoV patients, in which chloroquine inhibited" exact="virus infection" post="by interfering with the terminal glycosylation of ACE2 receptor"/>
 <result pre="chloroquine treatment of SARS-CoV patients, in which chloroquine inhibited virus" exact="infection" post="by interfering with the terminal glycosylation of ACE2 receptor"/>
 <result pre="X-Related View Sex-disparities have been often observed in response to" exact="communicable diseases" post="[107,117]. In viral infections, sex differences in term of"/>
 <result pre="been often observed in response to communicable diseases [107,117]. In" exact="viral" post="infections, sex differences in term of intensity, prevalence, severity,"/>
 <result pre="to show a greater humoral and cell-mediated immune response to" exact="infection" post="[117,118,119]. Consequently, females clear infections more quickly and more"/>
 <result pre="and cell-mediated immune response to infection [117,118,119]. Consequently, females clear" exact="infections" post="more quickly and more effectively than males [118,120,121]. Sex"/>
 <result pre="expression of genes on the X- and Y-chromosomes, since immune-related" exact="X-linked" post="genes appear to be more activated in female immune"/>
 <result pre="since immune-related X-linked genes appear to be more activated in" exact="female" post="immune cells. The sex chromosomes X and Y, which"/>
 <result pre="and permanently silence one of the two X-chromosomes of a" exact="female" post="individual. The process occurs at an early phase of"/>
 <result pre="adulthood. XCI is a strategy that aims to balance the" exact="X-linked" post="transcriptional dosage between female XX and male XY cells."/>
 <result pre="strategy that aims to balance the X-linked transcriptional dosage between" exact="female" post="XX and male XY cells. In general, 50% of"/>
 <result pre="female XX and male XY cells. In general, 50% of" exact="female" post="cells and all cells derived from them have the"/>
 <result pre="XCI results in a condition of â€œcell mosaicismâ€� in a" exact="female" post="individual, where a balanced expression of both parental X-linked"/>
 <result pre="a female individual, where a balanced expression of both parental" exact="X-linked" post="genes is expected [126]. This condition may provide females"/>
 <result pre="females with greater plasticity and adaptability in the response to" exact="infectious diseases" post="than males. When it comes to gene expression, females"/>
 <result pre="When it comes to gene expression, females may compensate adverse" exact="X-linked" post="mutations by using cells that carry the wild allele"/>
 <result pre="other X-chromosome [124]. However, it is clear that XCI is" exact="incomplete" post="in humans [127] and that the balance may be"/>
 <result pre="Xi also causes unbalance of the allelic dosage and of" exact="X-linked" post="transcription. This loss of mosaicism may lead to a"/>
 <result pre="mechanism of escaping silencing, it seems that about 15% of" exact="X-linked" post="genes can escape inactivation, so that they are expressed"/>
 <result pre="inactivation, so that they are expressed by both X-chromosomes in" exact="female" post="cells, whereas a further 10% vary among individuals for"/>
 <result pre="their silencing behavior. The level of expression is, however, always" exact="lower" post="in the escaped gene [128]. XCI escape signatures vary"/>
 <result pre="in a study carried out without distinguishing between male and" exact="female" post="cells [39] it was demonstrated that ACE2 is abundantly"/>
 <result pre="the expression of the ACE2 receptor is higher on oral" exact="mucosa" post="and tongue epithelial cells. A systematic survey of XCI"/>
 <result pre="the ACE2 receptor is higher on oral mucosa and tongue" exact="epithelial" post="cells. A systematic survey of XCI that integrated transcriptomes"/>
 <result pre="Epsteinâ€&quot;Barr virus (EBV)-transformed lymphocytes. This finding may be suggestive of" exact="lower" post="ACE2 expression in females due to the combination of"/>
 <result pre="expression in females due to the combination of the two" exact="X-linked" post="genes compared to the expression arising from the X-linked"/>
 <result pre="two X-linked genes compared to the expression arising from the" exact="X-linked" post="and a Y homologue in males [127]. Nevertheless, in"/>
 <result pre="shows an apparent negative correlation between ACE2 quantitative expression and" exact="infection" post="susceptibility and severity at population level [131]. Nevertheless, the"/>
 <result pre="the tissues they have tested are not those of the" exact="upper" post="respiratory tract, with the exception of the lung (and"/>
 <result pre="tissues they have tested are not those of the upper" exact="respiratory" post="tract, with the exception of the lung (and blood"/>
 <result pre="of sex hormones (which decrease with age) and reduced by" exact="systemic" post="inflammation [131]. This fascinating theory, which would support the"/>
 <result pre="in the future when more data will be available. 4." exact="Inflammatory" post="Processes: An X-Related View Sexual dimorphism in terms of"/>
 <result pre="prognosis has been reported for several inflammatory pathological conditions, including" exact="respiratory" post="diseases in which hormonal profile, genetic, and epigenetic factors"/>
 <result pre="seems to be improved in females who therefore show a" exact="lower" post="risk/vulnerability to several pathogens, while males are more exposed"/>
 <result pre="suggests that males tend to experience the worst prognosis in" exact="acute" post="inflammatory settings (e.g., sepsis) [134,135], while there is a"/>
 <result pre="a generalized inversion of prognosis between men and women in" exact="chronic" post="inflammatory conditions (e.g., asthma) [136,137]. In relation to SARS-CoV2,"/>
 <result pre="and epidemiological data indeed confirms that, in agreement with other" exact="respiratory" post="inflammatory diseases and consistent with previous MERS-CoV and SARS-CoV"/>
 <result pre="IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFÎ± in the" exact="peripheral" post="blood of intensive care unit (ICU) patients compared to"/>
 <result pre="storm might be strongly associated with the severity of the" exact="disease" post="[141]. The role of the cytokine storm in SARS-CoV-2"/>
 <result pre="disease [141]. The role of the cytokine storm in SARS-CoV-2" exact="infection" post="is attracting great attention as a crucial phase to"/>
 <result pre="However, since sex dimorphism observed in several inflammatory diseases, including" exact="respiratory" post="pathologies, has also been confirmed in studies dealing with"/>
 <result pre="Similarly, there is growing evidence suggesting that the X-chromosome and" exact="X-linked" post="genes are the main determinants of the reported sex"/>
 <result pre="are the main determinants of the reported sex dimorphism in" exact="disease" post="susceptibility and prognosis [8,148]. The X-chromosome carries about 1,200"/>
 <result pre="showing higher inflammatory response than in females and subjects with" exact="Klinefelter syndrome" post="who carry two X-chromosomes, but are characterized by a"/>
 <result pre="higher inflammatory response than in females and subjects with Klinefelter" exact="syndrome" post="who carry two X-chromosomes, but are characterized by a"/>
 <result pre="[151]. The presence of two X-chromosomes carrying genetic variants of" exact="X-linked" post="inflammatory genes/receptors undergoing random inactivation may therefore represent an"/>
 <result pre="undergoing random inactivation may therefore represent an advantage in the" exact="acute" post="phase of inflammatory diseases [151,152]. Finally, X-linked genes coding"/>
 <result pre="advantage in the acute phase of inflammatory diseases [151,152]. Finally," exact="X-linked" post="genes coding for inflammatory mediators/receptors may also escape XCI"/>
 <result pre="implications in sex-related differences of inflammatory responses [154]. Interestingly, the" exact="X-linked" post="ACE2 gene, in transgender males treated with estrogen therapy"/>
 <result pre="useful to modulate/balance inflammation [150]. The lessons learned from different" exact="respiratory" post="diseases of viral and non-viral origin, and preclinical research"/>
 <result pre="inflammation [150]. The lessons learned from different respiratory diseases of" exact="viral" post="and non-viral origin, and preclinical research suggest that the"/>
 <result pre="account for the low risk and better prognosis of SARS-CoV-2" exact="infection" post="in females, though a multidisciplinary approach for such complex"/>
 <result pre="in modifying womenâ€™s risk such as different comorbidity rates (e.g.," exact="hypertension" post="and cardiovascular diseases), smoking and drinking habits, personal hygiene,"/>
 <result pre="womenâ€™s risk such as different comorbidity rates (e.g., hypertension and" exact="cardiovascular" post="diseases), smoking and drinking habits, personal hygiene, the number"/>
 <result pre="smoking deserves particular consideration. Smoking is a risk for many" exact="respiratory" post="diseases and undoubtedly also for COVID-19 [155,156]. The European"/>
 <result pre="respiratory diseases and undoubtedly also for COVID-19 [155,156]. The European" exact="Respiratory" post="Society [157] reported results of different studies concluding that"/>
 <result pre="prevention measures. As regards the individual susceptibility of smokers toward" exact="respiratory" post="diseases, such as influenza, chronic obstructive pulmonary disease (COPD),"/>
 <result pre="individual susceptibility of smokers toward respiratory diseases, such as influenza," exact="chronic" post="obstructive pulmonary disease (COPD), tuberculosis (TB), or other lung"/>
 <result pre="of smokers toward respiratory diseases, such as influenza, chronic obstructive" exact="pulmonary" post="disease (COPD), tuberculosis (TB), or other lung pathological conditions,"/>
 <result pre="smokers toward respiratory diseases, such as influenza, chronic obstructive pulmonary" exact="disease" post="(COPD), tuberculosis (TB), or other lung pathological conditions, there"/>
 <result pre="respiratory diseases, such as influenza, chronic obstructive pulmonary disease (COPD)," exact="tuberculosis" post="(TB), or other lung pathological conditions, there are no"/>
 <result pre="about a direct association [161,162,163,164]. Accordingly, the European Centre for" exact="Disease" post="Prevention and Control (ECDC) suggested that smoking may contribute"/>
 <result pre="quality has been suggested to lead to an increased COVID-19" exact="infection" post="rate probability due to a direct effect of air"/>
 <result pre="the atmosphere, that by increasing general immune responses might affect" exact="viral" post="spread, speculating that it might also decrease during warm"/>
 <result pre="equipment are key issues [176] to avoid front-line healthcare worker" exact="infection" post="risk and increased psychological burden, particularly for medical doctors"/>
 <result pre="at such a high risk as hospital workers is of" exact="primary" post="importance. Efficient personal and protective equipment reduces mortality, and"/>
 <result pre="we need to plan strategies to ensure protection also against" exact="infections" post="rising from environmental sources. Therefore, any useful tool/instrument/product/action should"/>
 <result pre="benefit. Finally, considering individual genetic susceptibility or environmental influences on" exact="virus infection" post="and/or SARS progression, a wide and heterogeneous geographical distribution"/>
 <result pre="Finally, considering individual genetic susceptibility or environmental influences on virus" exact="infection" post="and/or SARS progression, a wide and heterogeneous geographical distribution"/>
 <result pre="the second area of Italy for absolute number of SARS-CoV-2" exact="infections" post="(26,487 confirmed cases/4,452,638 habitants; male/female ratio 48.6/51.4). It accounts"/>
 <result pre="cases/4,452,638 habitants; male/female ratio 48.6/51.4). It accounts for an overall" exact="infection" post="rate of about 0.59%, characterized by 3,366 deaths (14.2%"/>
 <result pre="deaths (14.2% death rate), considering 217,039 performed tests and 1899" exact="total" post="recovered patients (7 May 2020, 7:00 PM). Among the"/>
 <result pre="confirmed cases/346,975 habitants; male/female ratio 48.1/51.9) accounting for an overall" exact="infection" post="rate of about 0.27%, compared with the town of"/>
 <result pre="confirmed cases/286,781 habitants; male/female ratio 48.9/51.1) accounting for an overall" exact="infection" post="ratio of about 1.5% (Ferrara vs. Piacenza; p&amp;lt; 0.00001;"/>
 <result pre="is very close to the most critical hot-spot of the" exact="infection" post="in Italy [region Lombardia (0.83%); Lodi (1.43%), Codogno area"/>
 <result pre="population density may account for local differences in terms of" exact="viral" post="spreading (Ferrara: 325 habitants/Km2 vs. Piacenza 880 habitants/Km2). Genetic"/>
 <result pre="Genetic selection pressure by previous epidemics, such as the long-lasting" exact="malaria" post="epidemics in the Po river area where the city"/>
 <result pre="This is in line with some publications reporting that endemic" exact="malaria" post="seems to protect from COVID-19 outbreak and that genetic"/>
 <result pre="protect from COVID-19 outbreak and that genetic variations associated with" exact="malaria" post="(e.g., ACE2 and ABO genes) may play protective roles"/>
 <result pre="pandemic by coronavirus SARS-CoV-2, is a severe, complex, and multifactorial" exact="disease" post="in which human genetics, due to inherited predispositions, could"/>
 <result pre="predispositions, could play a role together with pre-existing comorbidities and" exact="acquired" post="risk conditions. Unmodifiable factors, such as age and sex,"/>
 <result pre="factors, such as age and sex, together with modifiable classical" exact="cardiovascular" post="risk factors and comorbidities play crucial roles in tuning"/>
 <result pre="with a more refined approach by the dynamic assessing of" exact="residual" post="FXIIIA levels, as recently suggested during any acute thrombotic"/>
 <result pre="assessing of residual FXIIIA levels, as recently suggested during any" exact="acute" post="thrombotic event [182,183]. The unexpected reported higher expression of"/>
 <result pre="mechanisms (though unfortunately sex-hormones decrease with age) and exacerbated by" exact="systemic" post="inflammation (which unfortunately increases with age and chronic diseases)"/>
 <result pre="exacerbated by systemic inflammation (which unfortunately increases with age and" exact="chronic" post="diseases) [131]. Part of the present findings were already"/>
 <result pre="Different sex and age groups have strongly different susceptibilities to" exact="infection" post="and mortality, considering male-sex, old age, and comorbidities as"/>
 <result pre="been speculated to explain some controversial data. Considering individual genetic" exact="susceptibility to" post="virus infection and progression, heterogeneous geographical distributions are now"/>
 <result pre="to explain some controversial data. Considering individual genetic susceptibility to" exact="virus infection" post="and progression, heterogeneous geographical distributions are now emerging not"/>
 <result pre="explain some controversial data. Considering individual genetic susceptibility to virus" exact="infection" post="and progression, heterogeneous geographical distributions are now emerging not"/>
 <result pre="1.ZakiA.M.van BoheemenS.BestebroerT.M.OsterhausA.D.FouchierR.A.Isolation of a novel coronavirus from a man with" exact="pneumonia" post="in Saudi ArabiaN. Engl. J. Med.20123671814182010.1056/NEJMoa121172123075143 2.PeirisJ.S.GuanY.YuenK.Y.Severe acute respiratory"/>
 <result pre="man with pneumonia in Saudi ArabiaN. Engl. J. Med.20123671814182010.1056/NEJMoa121172123075143 2.PeirisJ.S.GuanY.YuenK.Y.Severe" exact="acute" post="respiratory syndromeNat. Med.200410S88S9710.1038/nm114315577937 3.MenacheryV.D.YountB.L.Jr.DebbinkK.AgnihothramS.GralinskiL.E.PlanteJ.A.GrahamR.L.ScobeyT.GeX.Y.DonaldsonE.F.et al.A SARS-like cluster of circulating"/>
 <result pre="with pneumonia in Saudi ArabiaN. Engl. J. Med.20123671814182010.1056/NEJMoa121172123075143 2.PeirisJ.S.GuanY.YuenK.Y.Severe acute" exact="respiratory" post="syndromeNat. Med.200410S88S9710.1038/nm114315577937 3.MenacheryV.D.YountB.L.Jr.DebbinkK.AgnihothramS.GralinskiL.E.PlanteJ.A.GrahamR.L.ScobeyT.GeX.Y.DonaldsonE.F.et al.A SARS-like cluster of circulating bat"/>
 <result pre="shows potential for human emergenceNat. Med.2015211508151310.1038/nm.398526552008 4.AlagailiA.N.BrieseT.MishraN.KapoorV.SameroffS.C.BurbeloP.D.de WitE.MunsterV.J.HensleyL.E.ZalmoutI.S.et al.Middle East" exact="respiratory" post="syndrome coronavirus infection in dromedary camels in Saudi ArabiamBio20145e00884-1410.1128/mBio.00884-1424570370"/>
 <result pre="potential for human emergenceNat. Med.2015211508151310.1038/nm.398526552008 4.AlagailiA.N.BrieseT.MishraN.KapoorV.SameroffS.C.BurbeloP.D.de WitE.MunsterV.J.HensleyL.E.ZalmoutI.S.et al.Middle East respiratory" exact="syndrome" post="coronavirus infection in dromedary camels in Saudi ArabiamBio20145e00884-1410.1128/mBio.00884-1424570370 5.DrostenC.GuntherS.PreiserW.van"/>
 <result pre="human emergenceNat. Med.2015211508151310.1038/nm.398526552008 4.AlagailiA.N.BrieseT.MishraN.KapoorV.SameroffS.C.BurbeloP.D.de WitE.MunsterV.J.HensleyL.E.ZalmoutI.S.et al.Middle East respiratory syndrome coronavirus" exact="infection" post="in dromedary camels in Saudi ArabiamBio20145e00884-1410.1128/mBio.00884-1424570370 5.DrostenC.GuntherS.PreiserW.van der WerfS.BrodtH.R.BeckerS.RabenauH.PanningM.KolesnikovaL.FouchierR.A.et"/>
 <result pre="WerfS.BrodtH.R.BeckerS.RabenauH.PanningM.KolesnikovaL.FouchierR.A.et al.Identification of a novel coronavirus in patients with severe" exact="acute" post="respiratory syndromeN. Engl. J. Med.20033481967197610.1056/NEJMoa03074712690091 6.KuikenT.FouchierR.A.SchuttenM.RimmelzwaanG.F.van AmerongenG.van RielD.LamanJ.D.de JongT.van"/>
 <result pre="al.Identification of a novel coronavirus in patients with severe acute" exact="respiratory" post="syndromeN. Engl. J. Med.20033481967197610.1056/NEJMoa03074712690091 6.KuikenT.FouchierR.A.SchuttenM.RimmelzwaanG.F.van AmerongenG.van RielD.LamanJ.D.de JongT.van DoornumG.LimW.et"/>
 <result pre="6.KuikenT.FouchierR.A.SchuttenM.RimmelzwaanG.F.van AmerongenG.van RielD.LamanJ.D.de JongT.van DoornumG.LimW.et al.Newly discovered coronavirus as the" exact="primary" post="cause of severe acute respiratory syndromeLancet200336226327010.1016/S0140-6736(03)13967-012892955 7.ChannappanavarR.FettC.MackM.Ten EyckP.P.MeyerholzD.K.PerlmanS.Sex-Based Differences"/>
 <result pre="DoornumG.LimW.et al.Newly discovered coronavirus as the primary cause of severe" exact="acute" post="respiratory syndromeLancet200336226327010.1016/S0140-6736(03)13967-012892955 7.ChannappanavarR.FettC.MackM.Ten EyckP.P.MeyerholzD.K.PerlmanS.Sex-Based Differences in Susceptibility to Severe"/>
 <result pre="al.Newly discovered coronavirus as the primary cause of severe acute" exact="respiratory" post="syndromeLancet200336226327010.1016/S0140-6736(03)13967-012892955 7.ChannappanavarR.FettC.MackM.Ten EyckP.P.MeyerholzD.K.PerlmanS.Sex-Based Differences in Susceptibility to Severe Acute"/>
 <result pre="cause of severe acute respiratory syndromeLancet200336226327010.1016/S0140-6736(03)13967-012892955 7.ChannappanavarR.FettC.MackM.Ten EyckP.P.MeyerholzD.K.PerlmanS.Sex-Based Differences in" exact="Susceptibility to" post="Severe Acute Respiratory Syndrome Coronavirus InfectionJ. Immunol.20171984046405310.4049/jimmunol.160189628373583 8.CasimirG.J.LefevreN.CorazzaF.DuchateauJ.Sex and"/>
 <result pre="severe acute respiratory syndromeLancet200336226327010.1016/S0140-6736(03)13967-012892955 7.ChannappanavarR.FettC.MackM.Ten EyckP.P.MeyerholzD.K.PerlmanS.Sex-Based Differences in Susceptibility to" exact="Severe" post="Acute Respiratory Syndrome Coronavirus InfectionJ. Immunol.20171984046405310.4049/jimmunol.160189628373583 8.CasimirG.J.LefevreN.CorazzaF.DuchateauJ.Sex and inflammation"/>
 <result pre="acute respiratory syndromeLancet200336226327010.1016/S0140-6736(03)13967-012892955 7.ChannappanavarR.FettC.MackM.Ten EyckP.P.MeyerholzD.K.PerlmanS.Sex-Based Differences in Susceptibility to Severe" exact="Acute" post="Respiratory Syndrome Coronavirus InfectionJ. Immunol.20171984046405310.4049/jimmunol.160189628373583 8.CasimirG.J.LefevreN.CorazzaF.DuchateauJ.Sex and inflammation in"/>
 <result pre="respiratory syndromeLancet200336226327010.1016/S0140-6736(03)13967-012892955 7.ChannappanavarR.FettC.MackM.Ten EyckP.P.MeyerholzD.K.PerlmanS.Sex-Based Differences in Susceptibility to Severe Acute" exact="Respiratory" post="Syndrome Coronavirus InfectionJ. Immunol.20171984046405310.4049/jimmunol.160189628373583 8.CasimirG.J.LefevreN.CorazzaF.DuchateauJ.Sex and inflammation in respiratory"/>
 <result pre="syndromeLancet200336226327010.1016/S0140-6736(03)13967-012892955 7.ChannappanavarR.FettC.MackM.Ten EyckP.P.MeyerholzD.K.PerlmanS.Sex-Based Differences in Susceptibility to Severe Acute Respiratory" exact="Syndrome" post="Coronavirus InfectionJ. Immunol.20171984046405310.4049/jimmunol.160189628373583 8.CasimirG.J.LefevreN.CorazzaF.DuchateauJ.Sex and inflammation in respiratory diseases:"/>
 <result pre="Acute Respiratory Syndrome Coronavirus InfectionJ. Immunol.20171984046405310.4049/jimmunol.160189628373583 8.CasimirG.J.LefevreN.CorazzaF.DuchateauJ.Sex and inflammation in" exact="respiratory" post="diseases: A clinical viewpointBiol. Sex Differ.201341610.1186/2042-6410-4-1624128344 9.NichollsJ.M.PoonL.L.LeeK.C.NgW.F.LaiS.T.LeungC.Y.ChuC.M.HuiP.K.MakK.L.LimW.et al.Lung pathology"/>
 <result pre="clinical viewpointBiol. Sex Differ.201341610.1186/2042-6410-4-1624128344 9.NichollsJ.M.PoonL.L.LeeK.C.NgW.F.LaiS.T.LeungC.Y.ChuC.M.HuiP.K.MakK.L.LimW.et al.Lung pathology of fatal severe" exact="acute" post="respiratory syndromeLancet20033611773177810.1016/S0140-6736(03)13413-712781536 10.ChenJ.SubbaraoK.The Immunobiology of SARS*Annu. Rev. Immunol.20072544347210.1146/annurev.immunol.25.022106.14170617243893 11.SuL.MaX.YuH.ZhangZ.BianP.HanY.SunJ.LiuY.YangC.GengJ.et"/>
 <result pre="viewpointBiol. Sex Differ.201341610.1186/2042-6410-4-1624128344 9.NichollsJ.M.PoonL.L.LeeK.C.NgW.F.LaiS.T.LeungC.Y.ChuC.M.HuiP.K.MakK.L.LimW.et al.Lung pathology of fatal severe acute" exact="respiratory" post="syndromeLancet20033611773177810.1016/S0140-6736(03)13413-712781536 10.ChenJ.SubbaraoK.The Immunobiology of SARS*Annu. Rev. Immunol.20072544347210.1146/annurev.immunol.25.022106.14170617243893 11.SuL.MaX.YuH.ZhangZ.BianP.HanY.SunJ.LiuY.YangC.GengJ.et al.The"/>
 <result pre="Rev. Immunol.20072544347210.1146/annurev.immunol.25.022106.14170617243893 11.SuL.MaX.YuH.ZhangZ.BianP.HanY.SunJ.LiuY.YangC.GengJ.et al.The different clinical characteristics of corona virus" exact="disease" post="cases between children and their families in Chinaâ€&quot;The character"/>
 <result pre="Microbes Infect.2020970771310.1080/22221751.2020.174448332208917 12.NgP.C.LamC.W.LiA.M.WongC.K.ChengF.W.LeungT.F.HonE.K.ChanI.H.LiC.K.FungK.S.et al.Inflammatory cytokine profile in children with severe" exact="acute" post="respiratory syndromePediatrics2004113e7e1410.1542/peds.113.1.e714702488 13.GemmatiD.SerinoM.L.TognazzoS.OngaroA.MoratelliS.GilliG.ForiniE.De MatteiM.ScapoliG.L.The reduced sensitivity of the ProC"/>
 <result pre="Infect.2020970771310.1080/22221751.2020.174448332208917 12.NgP.C.LamC.W.LiA.M.WongC.K.ChengF.W.LeungT.F.HonE.K.ChanI.H.LiC.K.FungK.S.et al.Inflammatory cytokine profile in children with severe acute" exact="respiratory" post="syndromePediatrics2004113e7e1410.1542/peds.113.1.e714702488 13.GemmatiD.SerinoM.L.TognazzoS.OngaroA.MoratelliS.GilliG.ForiniE.De MatteiM.ScapoliG.L.The reduced sensitivity of the ProC Global"/>
 <result pre="mutations in a thrombotic family is associated with recurrence and" exact="early onset" post="of venous thrombosisHaemostasis2001319910510.1159/00004805011684865 15.GemmatiD.SerinoM.L.MoratelliS.MariR.BalleriniG.ScapoliG.L.Coexistence of antithrombin deficiency, factor V"/>
 <result pre="venous thrombosisHaemostasis2001319910510.1159/00004805011684865 15.GemmatiD.SerinoM.L.MoratelliS.MariR.BalleriniG.ScapoliG.L.Coexistence of antithrombin deficiency, factor V Leiden and" exact="hyperhomocysteinemia" post="in a thrombotic familyBlood Coagul. Fibrinolysis1998917317610.1097/00001721-199803000-000089622215 16.GemmatiD.SerinoM.L.VerzolaI.MariR.MoratelliS.BalleriniG.Resistance to activated"/>
 <result pre="substitutionClin. Appl. Thromb. Hemost.1997316817310.1177/107602969700300304 18.YinS.HuangM.LiD.TangN.Difference of coagulation features between severe" exact="pneumonia" post="induced by SARS-CoV2 and non-SARS-CoV2J. Thromb. Thrombolysis202010.1007/s11239-020-02105-8 19.ShiS.QinM.ShenB.CaiY.LiuT.YangF.GongW.LiuX.LiangJ.ZhaoQ.et al.Association"/>
 <result pre="induced by SARS-CoV2 and non-SARS-CoV2J. Thromb. Thrombolysis202010.1007/s11239-020-02105-8 19.ShiS.QinM.ShenB.CaiY.LiuT.YangF.GongW.LiuX.LiangJ.ZhaoQ.et al.Association of" exact="Cardiac" post="Injury with Mortality in Hospitalized Patients with COVID-19 in"/>
 <result pre="22.TangN.BaiH.ChenX.GongJ.LiD.SunZ.Anticoagulant treatment is associated with decreased mortality in severe coronavirus" exact="disease" post="2019 patients with coagulopathyJ. Thromb. Haemost.202010.1111/jth.14817 23.KarlbergJ.ChongD.S.LaiW.Y.Do men have"/>
 <result pre="23.KarlbergJ.ChongD.S.LaiW.Y.Do men have a higher case fatality rate of severe" exact="acute" post="respiratory syndrome than women do?Am. J. Epidemiol.200415922923110.1093/aje/kwh05614742282 24.LeongH.N.EarnestA.LimH.H.ChinC.F.TanC.PuhaindranM.E.TanA.ChenM.I.LeoY.S.SARS in"/>
 <result pre="men have a higher case fatality rate of severe acute" exact="respiratory" post="syndrome than women do?Am. J. Epidemiol.200415922923110.1093/aje/kwh05614742282 24.LeongH.N.EarnestA.LimH.H.ChinC.F.TanC.PuhaindranM.E.TanA.ChenM.I.LeoY.S.SARS in Singapore--predictors"/>
 <result pre="have a higher case fatality rate of severe acute respiratory" exact="syndrome" post="than women do?Am. J. Epidemiol.200415922923110.1093/aje/kwh05614742282 24.LeongH.N.EarnestA.LimH.H.ChinC.F.TanC.PuhaindranM.E.TanA.ChenM.I.LeoY.S.SARS in Singapore--predictors of"/>
 <result pre="syndrome than women do?Am. J. Epidemiol.200415922923110.1093/aje/kwh05614742282 24.LeongH.N.EarnestA.LimH.H.ChinC.F.TanC.PuhaindranM.E.TanA.ChenM.I.LeoY.S.SARS in Singapore--predictors of" exact="disease" post="severityAnn. Acad. Med. Singap.20063532633116829999 25.AlghamdiI.G.HussainI.I.AlmalkiS.S.AlghamdiM.S.AlghamdiM.M.El-SheemyM.A.The pattern of Middle East"/>
 <result pre="disease severityAnn. Acad. Med. Singap.20063532633116829999 25.AlghamdiI.G.HussainI.I.AlmalkiS.S.AlghamdiM.S.AlghamdiM.M.El-SheemyM.A.The pattern of Middle East" exact="respiratory" post="syndrome coronavirus in Saudi Arabia: A descriptive epidemiological analysis"/>
 <result pre="severityAnn. Acad. Med. Singap.20063532633116829999 25.AlghamdiI.G.HussainI.I.AlmalkiS.S.AlghamdiM.S.AlghamdiM.M.El-SheemyM.A.The pattern of Middle East respiratory" exact="syndrome" post="coronavirus in Saudi Arabia: A descriptive epidemiological analysis of"/>
 <result pre="the Saudi Ministry of HealthInt. J. Gen. Med.2014741742310.2147/IJGM.S6706125187734 26.TzoranI.HoffmanR.MonrealM.Hemostasis and" exact="Thrombosis" post="in the Oldest OldSemin. Thromb. Hemost.20184462463110.1055/s-0038-165777929920621 27.KleinS.L.FlanaganK.L.Sex differences in"/>
 <result pre="Endocrinol. Metab.2004893313331810.1210/jc.2003-03106915240608 34.PeretzJ.PekoszA.LaneA.P.KleinS.L.Estrogenic compounds reduce influenza A virus replication in" exact="primary" post="human nasal epithelial cells derived from female, but not"/>
 <result pre="compounds reduce influenza A virus replication in primary human nasal" exact="epithelial" post="cells derived from female, but not male, donorsAm. J."/>
 <result pre="InhibitorCell202010.1016/j.cell.2020.02.052 36.XuH.ZhongL.DengJ.PengJ.DanH.ZengX.LiT.ChenQ.High expression of ACE2 receptor of 2019-nCoV on the" exact="epithelial" post="cells of oral mucosaInt. J. Oral Sci.202012810.1038/s41368-020-0074-x32094336 37.ZhangH.PenningerJ.M.LiY.ZhongN.SlutskyA.S.Angiotensin-converting enzyme"/>
 <result pre="TMPRSS2 and HAT are expressed at multiple sites in human" exact="respiratory" post="and gastrointestinal tractsPLoS ONE20127e3587610.1371/journal.pone.003587622558251 39.HammingI.TimensW.BulthuisM.L.LelyA.T.NavisG.van GoorH.Tissue distribution of ACE2"/>
 <result pre="43.ChiuR.W.TangN.L.HuiD.S.ChungG.T.ChimS.S.ChanK.C.SungY.M.ChanL.Y.TongY.K.LeeW.S.et al.ACE2 gene polymorphisms do not affect outcome of severe" exact="acute" post="respiratory syndromeClin. Chem.2004501683168610.1373/clinchem.2004.03543615331509 44.AsseltaR.ParaboschiE.M.MantovaniA.DugaS.ACE2 and TMPRSS2 variants and expression"/>
 <result pre="al.ACE2 gene polymorphisms do not affect outcome of severe acute" exact="respiratory" post="syndromeClin. Chem.2004501683168610.1373/clinchem.2004.03543615331509 44.AsseltaR.ParaboschiE.M.MantovaniA.DugaS.ACE2 and TMPRSS2 variants and expression as"/>
 <result pre="fusion co-opts master transcription factors and activates NOTCH signaling in" exact="primary" post="prostate cancerNat. Genet.2017491336134510.1038/ng.393028783165 46.ChengZ.ZhouJ.ToK.K.ChuH.LiC.WangD.YangD.ZhengS.HaoK.BosseY.et al.Identification of TMPRSS2 as a"/>
 <result pre="Genet.2017491336134510.1038/ng.393028783165 46.ChengZ.ZhouJ.ToK.K.ChuH.LiC.WangD.YangD.ZhengS.HaoK.BosseY.et al.Identification of TMPRSS2 as a Susceptibility Gene for" exact="Severe" post="2009 Pandemic A(H1N1) Influenza and A(H7N9) InfluenzaJ. Infect. Dis20152121214122110.1093/infdis/jiv24625904605"/>
 <result pre="Infect. Dis20152121214122110.1093/infdis/jiv24625904605 47.BaenaE.ShaoZ.LinnD.E.GlassK.HamblenM.J.FujiwaraY.KimJ.NguyenM.ZhangX.GodinhoF.J.et al.ETV1 directs androgen metabolism and confers aggressive" exact="prostate cancer" post="in targeted mice and patientsGenes Dev.20132768369810.1101/gad.211011.11223512661 48.TikellisC.ThomasM.C.Angiotensin-Converting Enzyme 2"/>
 <result pre="Dis20152121214122110.1093/infdis/jiv24625904605 47.BaenaE.ShaoZ.LinnD.E.GlassK.HamblenM.J.FujiwaraY.KimJ.NguyenM.ZhangX.GodinhoF.J.et al.ETV1 directs androgen metabolism and confers aggressive prostate" exact="cancer" post="in targeted mice and patientsGenes Dev.20132768369810.1101/gad.211011.11223512661 48.TikellisC.ThomasM.C.Angiotensin-Converting Enzyme 2"/>
 <result pre="DiseaseInt. J. Pept.2012201225629410.1155/2012/25629422536270 49.CrowleyS.D.GurleyS.B.OliverioM.I.PazminoA.K.GriffithsR.FlanneryP.J.SpurneyR.F.KimH.S.SmithiesO.LeT.H.et al.Distinct roles for the kidney and" exact="systemic" post="tissues in blood pressure regulation by the renin-angiotensin systemJ."/>
 <result pre="chromatography/mass spectrometry to evaluate ACE/ACE2 balance in endothelial dysfunction and" exact="vascular" post="pathologiesPharm. Rep.20156777878510.1016/j.pharep.2015.03.01726321281 54.Fraga-SilvaR.A.SorgB.S.WankhedeM.DedeugdC.JunJ.Y.BakerM.B.LiY.CastellanoR.K.KatovichM.J.RaizadaM.K.et al.ACE2 activation promotes antithrombotic activityMol. Med.20101621021510.2119/molmed.2009.0016020111697"/>
 <result pre="of Wuhan 2019-nCovBioRxiv202010.1101/2020.01.26.919985 58.ImaiY.KubaK.RaoS.HuanY.GuoF.GuanB.YangP.SaraoR.WadaT.Leong-PoiH.et al.Angiotensin-converting enzyme 2 protects from severe" exact="acute" post="lung failureNature200543611211610.1038/nature0371216001071 59.VicenziE.CanducciF.PinnaD.ManciniN.CarlettiS.LazzarinA.BordignonC.PoliG.ClementiM.Coronaviridae and SARS-associated coronavirus strain HSR1Emerg. Infect."/>
 <result pre="sulfate is a selective attachment factor for the avian coronavirus" exact="infectious" post="bronchitis virus BeaudetteAvian Dis.200751455110.1637/0005-2086(2007)051[0045:HSIASA]2.0.CO;217461266 62.LangJ.YangN.DengJ.LiuK.YangP.ZhangG.JiangC.Inhibition of SARS pseudovirus cell"/>
 <result pre="is a selective attachment factor for the avian coronavirus infectious" exact="bronchitis" post="virus BeaudetteAvian Dis.200751455110.1637/0005-2086(2007)051[0045:HSIASA]2.0.CO;217461266 62.LangJ.YangN.DengJ.LiuK.YangP.ZhangG.JiangC.Inhibition of SARS pseudovirus cell entry"/>
 <result pre="66.CrackowerM.A.SaraoR.OuditG.Y.YagilC.KozieradzkiI.ScangaS.E.Oliveira-dos-SantosA.J.da CostaJ.ZhangL.PeiY.et al.Angiotensin-converting enzyme 2 is an essential regulator of" exact="heart" post="functionNature200241782282810.1038/nature0078612075344 67.NakamuraK.KoibuchiN.NishimatsuH.HigashikuniY.HirataY.KugiyamaK.NagaiR.SataM.Candesartan ameliorates cardiac dysfunction observed in angiotensin-converting enzyme"/>
 <result pre="pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in" exact="acute" post="respiratory distress syndromeCrit. Care20172123410.1186/s13054-017-1823-x28877748 70.ZhangH.BakerA.Recombinant human ACE2: Acing out"/>
 <result pre="clinical trial of recombinant human angiotensin-converting enzyme 2 in acute" exact="respiratory" post="distress syndromeCrit. Care20172123410.1186/s13054-017-1823-x28877748 70.ZhangH.BakerA.Recombinant human ACE2: Acing out angiotensin"/>
 <result pre="Respir. Crit. Care Med.201519231532310.1164/rccm.201412-2326OC25945397 74.Wosten-van AsperenR.M.LutterR.SpechtP.A.MollG.N.van WoenselJ.B.van der LoosC.M.van GoorH.KamilicJ.FlorquinS.BosA.P.Acute" exact="respiratory" post="distress syndrome leads to reduced ratio of ACE/ACE2 activities"/>
 <result pre="Care Med.201519231532310.1164/rccm.201412-2326OC25945397 74.Wosten-van AsperenR.M.LutterR.SpechtP.A.MollG.N.van WoenselJ.B.van der LoosC.M.van GoorH.KamilicJ.FlorquinS.BosA.P.Acute respiratory distress" exact="syndrome" post="leads to reduced ratio of ACE/ACE2 activities and is"/>
 <result pre="of angiotensin-converting enzyme I/D polymorphism as a risk factor for" exact="preeclampsia" post="in Chinese womenGenet. Mol. Res.2012112268227610.4238/2012.May.21.122653650 81.MizuiriS.HemmiH.KumanomidouH.IwamotoM.MiyagiM.SakaiK.AikawaA.OharaT.YamadaK.ShimatakeH.et al.Angiotensin-converting enzyme (ACE)"/>
 <result pre="enzyme insertion/deletion polymorphism is associated with susceptibility and outcome in" exact="acute" post="respiratory distress syndromeAm. J. Respir. Crit. Care Med.200216664665010.1164/rccm.210808612204859 84.JerngJ.S.YuC.J.WangH.C.ChenK.Y.ChengS.L.YangP.C.Polymorphism"/>
 <result pre="insertion/deletion polymorphism is associated with susceptibility and outcome in acute" exact="respiratory" post="distress syndromeAm. J. Respir. Crit. Care Med.200216664665010.1164/rccm.210808612204859 84.JerngJ.S.YuC.J.WangH.C.ChenK.Y.ChengS.L.YangP.C.Polymorphism of"/>
 <result pre="84.JerngJ.S.YuC.J.WangH.C.ChenK.Y.ChengS.L.YangP.C.Polymorphism of the angiotensin-converting enzyme gene affects the outcome of" exact="acute" post="respiratory distress syndromeCrit. Care Med.2006341001100610.1097/01.CCM.0000206107.92476.3916484896 85.ChanK.C.TangN.L.HuiD.S.ChungG.T.WuA.K.ChimS.S.ChiuR.W.LeeN.ChoiK.W.SungY.M.et al.Absence of association"/>
 <result pre="of the angiotensin-converting enzyme gene affects the outcome of acute" exact="respiratory" post="distress syndromeCrit. Care Med.2006341001100610.1097/01.CCM.0000206107.92476.3916484896 85.ChanK.C.TangN.L.HuiD.S.ChungG.T.WuA.K.ChimS.S.ChiuR.W.LeeN.ChoiK.W.SungY.M.et al.Absence of association between"/>
 <result pre="of association between angiotensin converting enzyme polymorphism and development of" exact="adult" post="respiratory distress syndrome in patients with severe acute respiratory"/>
 <result pre="association between angiotensin converting enzyme polymorphism and development of adult" exact="respiratory" post="distress syndrome in patients with severe acute respiratory syndrome:"/>
 <result pre="angiotensin converting enzyme polymorphism and development of adult respiratory distress" exact="syndrome" post="in patients with severe acute respiratory syndrome: A case"/>
 <result pre="development of adult respiratory distress syndrome in patients with severe" exact="acute" post="respiratory syndrome: A case control studyBMC Infect. Dis.200552610.1186/1471-2334-5-2615819995 86.OrucN.LambJ.WhitcombD.J.SassD.A.The"/>
 <result pre="of adult respiratory distress syndrome in patients with severe acute" exact="respiratory" post="syndrome: A case control studyBMC Infect. Dis.200552610.1186/1471-2334-5-2615819995 86.OrucN.LambJ.WhitcombD.J.SassD.A.The ACE"/>
 <result pre="Dis.200552610.1186/1471-2334-5-2615819995 86.OrucN.LambJ.WhitcombD.J.SassD.A.The ACE gene I/D polymorphism does not affect the" exact="susceptibility to" post="or prognosis of PBCTurk. J. Gastroenterol.20081925025319119484 87.ZhangY.F.ChengQ.TangN.L.ChuT.T.TomlinsonB.LiuF.KwokT.C.Gender difference of"/>
 <result pre="polymorphism of angiotensin I-converting enzyme (ACE), but not angiotensin II" exact="type I" post="receptor (ATr1), has a gender-specific role in panic disorderPsychiatry"/>
 <result pre="Neurosci.20126613013710.1111/j.1440-1819.2011.02318.x22353325 89.SrivastavaK.SrivastavaA.MittalB.Angiotensin I-converting enzyme insertion/deletion polymorphism and increased risk of" exact="gall bladder cancer" post="in womenDNA Cell Biol.20102941742210.1089/dna.2010.103320438364 90.LuoJ.Q.HeF.Z.LuoZ.Y.WenJ.G.WangL.Y.SunN.L.TangG.F.LiQ.GuoD.LiuZ.Q.et al.Rs495828 polymorphism of the"/>
 <result pre="89.SrivastavaK.SrivastavaA.MittalB.Angiotensin I-converting enzyme insertion/deletion polymorphism and increased risk of gall" exact="bladder cancer" post="in womenDNA Cell Biol.20102941742210.1089/dna.2010.103320438364 90.LuoJ.Q.HeF.Z.LuoZ.Y.WenJ.G.WangL.Y.SunN.L.TangG.F.LiQ.GuoD.LiuZ.Q.et al.Rs495828 polymorphism of the"/>
 <result pre="I-converting enzyme insertion/deletion polymorphism and increased risk of gall bladder" exact="cancer" post="in womenDNA Cell Biol.20102941742210.1089/dna.2010.103320438364 90.LuoJ.Q.HeF.Z.LuoZ.Y.WenJ.G.WangL.Y.SunN.L.TangG.F.LiQ.GuoD.LiuZ.Q.et al.Rs495828 polymorphism of the"/>
 <result pre="97.PinheiroD.S.SantosR.S.JardimP.SilvaE.G.ReisA.A.S.PedrinoG.R.UlhoaC.J.The combination of ACE I/D and ACE2 G8790A polymorphisms revels" exact="susceptibility to" post="hypertension: A genetic association study in Brazilian patientsPLoS ONE201914e022124810.1371/journal.pone.022124831430320"/>
 <result pre="polymorphisms revels susceptibility to hypertension: A genetic association study in" exact="Brazilian" post="patientsPLoS ONE201914e022124810.1371/journal.pone.022124831430320 98.WuY.H.LiJ.Y.WangC.ZhangL.M.QiaoH.The ACE2 G8790A Polymorphism: Involvement in Type"/>
 <result pre="in Brazilian patientsPLoS ONE201914e022124810.1371/journal.pone.022124831430320 98.WuY.H.LiJ.Y.WangC.ZhangL.M.QiaoH.The ACE2 G8790A Polymorphism: Involvement in" exact="Type 2" post="Diabetes Mellitus Combined with Cerebral StrokeJ. Clin. Lab. Anal.20173110.1002/jcla.22033"/>
 <result pre="patientsPLoS ONE201914e022124810.1371/journal.pone.022124831430320 98.WuY.H.LiJ.Y.WangC.ZhangL.M.QiaoH.The ACE2 G8790A Polymorphism: Involvement in Type 2" exact="Diabetes Mellitus" post="Combined with Cerebral StrokeJ. Clin. Lab. Anal.20173110.1002/jcla.22033 99.YangM.ZhaoJ.XingL.ShiL.The association"/>
 <result pre="98.WuY.H.LiJ.Y.WangC.ZhangL.M.QiaoH.The ACE2 G8790A Polymorphism: Involvement in Type 2 Diabetes Mellitus" exact="Combined" post="with Cerebral StrokeJ. Clin. Lab. Anal.20173110.1002/jcla.22033 99.YangM.ZhaoJ.XingL.ShiL.The association between"/>
 <result pre="G8790A Polymorphism: Involvement in Type 2 Diabetes Mellitus Combined with" exact="Cerebral" post="StrokeJ. Clin. Lab. Anal.20173110.1002/jcla.22033 99.YangM.ZhaoJ.XingL.ShiL.The association between angiotensin-converting enzyme"/>
 <result pre="Lab. Anal.20173110.1002/jcla.22033 99.YangM.ZhaoJ.XingL.ShiL.The association between angiotensin-converting enzyme 2 polymorphisms and" exact="essential hypertension" post="risk: A meta-analysis involving 14,122 patientsJ. Renin Angiotensin Aldosterone"/>
 <result pre="Anal.20173110.1002/jcla.22033 99.YangM.ZhaoJ.XingL.ShiL.The association between angiotensin-converting enzyme 2 polymorphisms and essential" exact="hypertension" post="risk: A meta-analysis involving 14,122 patientsJ. Renin Angiotensin Aldosterone"/>
 <result pre="Syst.2015161240124410.1177/147032031454922125237167 100.LiY.Y.Lack of Association of ACE2 G8790A Gene Mutation with" exact="Essential" post="Hypertension in the Chinese Population: A Meta-Analysis Involving 5260"/>
 <result pre="100.LiY.Y.Lack of Association of ACE2 G8790A Gene Mutation with Essential" exact="Hypertension" post="in the Chinese Population: A Meta-Analysis Involving 5260 SubjectsFront."/>
 <result pre="102.HuangW.YangW.WangY.ZhaoQ.GuD.ChenR.Association study of angiotensin-converting enzyme 2 gene (ACE2) polymorphisms and" exact="essential hypertension" post="in northern Han ChineseJ. Hum. Hypertens.20062096897110.1038/sj.jhh.100209017024138 103.ImaiY.KubaK.PenningerJ.M.[Lessons from SARS:"/>
 <result pre="study of angiotensin-converting enzyme 2 gene (ACE2) polymorphisms and essential" exact="hypertension" post="in northern Han ChineseJ. Hum. Hypertens.20062096897110.1038/sj.jhh.100209017024138 103.ImaiY.KubaK.PenningerJ.M.[Lessons from SARS:"/>
 <result pre="Hum. Hypertens.20062096897110.1038/sj.jhh.100209017024138 103.ImaiY.KubaK.PenningerJ.M.[Lessons from SARS: A new potential therapy for" exact="acute" post="respiratory distress syndrome (ARDS) with angiotensin converting enzyme 2"/>
 <result pre="Hypertens.20062096897110.1038/sj.jhh.100209017024138 103.ImaiY.KubaK.PenningerJ.M.[Lessons from SARS: A new potential therapy for acute" exact="respiratory" post="distress syndrome (ARDS) with angiotensin converting enzyme 2 (ACE2)]Masui20085730231018340998"/>
 <result pre="from SARS: A new potential therapy for acute respiratory distress" exact="syndrome" post="(ARDS) with angiotensin converting enzyme 2 (ACE2)]Masui20085730231018340998 104.WrappD.WangN.CorbettK.S.GoldsmithJ.A.HsiehC.-L.AbionaO.GrahamB.S.McLellanJ.S.Cryo-EM structure"/>
 <result pre="with receptorScience20053091864186810.1126/science.111648016166518 109.VincentM.J.BergeronE.BenjannetS.EricksonB.R.RollinP.E.KsiazekT.G.SeidahN.G.NicholS.T.Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spreadVirol. J.200526910.1186/1743-422X-2-6916115318 110.ZamboniP.GemmatiD.Clinical implications of gene polymorphisms in"/>
 <result pre="XIIIA-V34L and factor XIIIB-H95R gene variants: Effects on survival in" exact="myocardial infarction" post="patientsMol. Med.20071311212010.2119/2006-00049.Gemmati17515963 112.TognazzoS.GemmatiD.PalazzoA.CatozziL.CarandinaS.LegnaroA.TacconiG.ScapoliG.L.ZamboniP.Prognostic role of factor XIII gene variants"/>
 <result pre="PalmaM.IzzoM.De MatteiM.OngaroA.ScapoliG.L.et al.Factor XIII V34L polymorphism modulates the risk of" exact="chronic" post="venous leg ulcer progression and extensionWound Repair Regen.20041251251710.1111/j.1067-1927.2004.012503.x15453833 115.GemmatiD.OcchionorelliS.TisatoV.ViglianoM.LongoG.GonelliA.SibillaM.G.SerinoM.L.ZamboniP.Inherited"/>
 <result pre="al.Maternal Haplotypes in DHFR Promoter and MTHFR Gene in Tuning" exact="Childhood" post="Acute Lymphoblastic Leukemia Onset-Latency: Genetic/Epigenetic Mother/Child Dyad Study (GEMCDS)Genes20191063410.3390/genes1009063431443485"/>
 <result pre="Haplotypes in DHFR Promoter and MTHFR Gene in Tuning Childhood" exact="Acute" post="Lymphoblastic Leukemia Onset-Latency: Genetic/Epigenetic Mother/Child Dyad Study (GEMCDS)Genes20191063410.3390/genes1009063431443485 117.SyrettC.M.AngueraM.C.When"/>
 <result pre="in DHFR Promoter and MTHFR Gene in Tuning Childhood Acute" exact="Lymphoblastic" post="Leukemia Onset-Latency: Genetic/Epigenetic Mother/Child Dyad Study (GEMCDS)Genes20191063410.3390/genes1009063431443485 117.SyrettC.M.AngueraM.C.When the"/>
 <result pre="DHFR Promoter and MTHFR Gene in Tuning Childhood Acute Lymphoblastic" exact="Leukemia" post="Onset-Latency: Genetic/Epigenetic Mother/Child Dyad Study (GEMCDS)Genes20191063410.3390/genes1009063431443485 117.SyrettC.M.AngueraM.C.When the balance"/>
 <result pre="Genetic/Epigenetic Mother/Child Dyad Study (GEMCDS)Genes20191063410.3390/genes1009063431443485 117.SyrettC.M.AngueraM.C.When the balance is broken:" exact="X-linked" post="gene dosage from two X chromosomes and female-biased autoimmunityJ."/>
 <result pre="responses to viruses, and efficacy of prophylaxis and treatments for" exact="viral" post="diseasesBioessays2012341050105910.1002/bies.20120009923012250 119.KleinS.L.JedlickaA.PekoszA.The Xs and Y of immune responses to"/>
 <result pre="viral diseasesBioessays2012341050105910.1002/bies.20120009923012250 119.KleinS.L.JedlickaA.PekoszA.The Xs and Y of immune responses to" exact="viral" post="vaccinesLancet Infect. Dis.20101033834910.1016/S1473-3099(10)70049-920417416 120.FishE.N.The X-files in immunity: Sex-based differences"/>
 <result pre="immune responsesNat. Rev. Immunol.2008873774410.1038/nri239418728636 121.UbedaF.JansenV.A.The evolution of sex-specific virulence in" exact="infectious" post="diseasesNat. Commun.201671384910.1038/ncomms1384927959327 122.KleinS.L.MarriottI.FishE.N.Sex-based differences in immune function and responses"/>
 <result pre="Trop. Med. Hyg.201510991510.1093/trstmh/tru16725573105 123.SchurzH.SalieM.TrompG.HoalE.G.KinnearC.J.MollerM.The X chromosome and sex-specific effects in" exact="infectious disease" post="susceptibilityHum. Genom.201913210.1186/s40246-018-0185-z30621780 124.LyonM.F.Gene action in the X-chromosome of the"/>
 <result pre="Med. Hyg.201510991510.1093/trstmh/tru16725573105 123.SchurzH.SalieM.TrompG.HoalE.G.KinnearC.J.MollerM.The X chromosome and sex-specific effects in infectious" exact="disease" post="susceptibilityHum. Genom.201913210.1186/s40246-018-0185-z30621780 124.LyonM.F.Gene action in the X-chromosome of the"/>
 <result pre="Soc. Lond. B Biol. Sci.201737210.1098/rstb.2016.035628947655 126.ZitoA.DaviesM.N.TsaiP.C.RobertsS.Andres-EjarqueR.NardoneS.BellJ.T.WongC.C.Y.SmallK.S.Heritability of skewed X-inactivation in" exact="female" post="twins is tissue-specific and associated with ageNat. Commun.201910533910.1038/s41467-019-13340-w31767861 127.TukiainenT.VillaniA.C.YenA.RivasM.A.MarshallJ.L.SatijaR.AguirreM.GauthierL.FlehartyM.KirbyA.et"/>
 <result pre="across human tissuesNature201755024424810.1038/nature2426529022598 128.WangJ.SyrettC.M.KramerM.C.BasuA.AtchisonM.L.AngueraM.C.Unusual maintenance of X chromosome inactivation predisposes" exact="female" post="lymphocytes for increased expression from the inactive XProc. Natl."/>
 <result pre="L. casei 431 on immune response to influenza vaccination and" exact="upper" post="respiratory tract infections in healthy adult volunteers: A randomized,"/>
 <result pre="casei 431 on immune response to influenza vaccination and upper" exact="respiratory" post="tract infections in healthy adult volunteers: A randomized, double-blind,"/>
 <result pre="on immune response to influenza vaccination and upper respiratory tract" exact="infections" post="in healthy adult volunteers: A randomized, double-blind, placebo-controlled, parallel-group"/>
 <result pre="to influenza vaccination and upper respiratory tract infections in healthy" exact="adult" post="volunteers: A randomized, double-blind, placebo-controlled, parallel-group studyAm. J. Clin."/>
 <result pre="and Gender in Inflammation: A Mini-ReviewFront. Immunol.2018947510.3389/fimmu.2018.0047529593728 136.PostmaD.S.Gender differences in" exact="asthma" post="development and progressionGend. Med.20074Suppl. BS133S14610.1016/s1550-8579(07)80054-418156099 137.TownsendE.A.MillerV.M.PrakashY.S.Sex differences and sex"/>
 <result pre="and clinical characteristics of 99 cases of 2019 novel coronavirus" exact="pneumonia" post="in Wuhan, China: A descriptive studyLancet202039550751310.1016/S0140-6736(20)30211-732007143 139.BadawiA.RyooS.G.Prevalence of comorbidities"/>
 <result pre="A descriptive studyLancet202039550751310.1016/S0140-6736(20)30211-732007143 139.BadawiA.RyooS.G.Prevalence of comorbidities in the Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV): A systematic review and meta-analysisInt. J."/>
 <result pre="descriptive studyLancet202039550751310.1016/S0140-6736(20)30211-732007143 139.BadawiA.RyooS.G.Prevalence of comorbidities in the Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV): A systematic review and meta-analysisInt. J. Infect."/>
 <result pre="Dis.20164912913310.1016/j.ijid.2016.06.01527352628 140.collab: World Health OrganizationConsensus Document on the Epidemiology of" exact="Severe" post="Acute Respiratory Syndrome (SARS)Available online: https://apps.who.int/iris/bitstream/handle/10665/70863/WHO_CDS_CSR_GAR_2003.11_eng.pdf(accessed on 26 March"/>
 <result pre="140.collab: World Health OrganizationConsensus Document on the Epidemiology of Severe" exact="Acute" post="Respiratory Syndrome (SARS)Available online: https://apps.who.int/iris/bitstream/handle/10665/70863/WHO_CDS_CSR_GAR_2003.11_eng.pdf(accessed on 26 March 2020)"/>
 <result pre="World Health OrganizationConsensus Document on the Epidemiology of Severe Acute" exact="Respiratory" post="Syndrome (SARS)Available online: https://apps.who.int/iris/bitstream/handle/10665/70863/WHO_CDS_CSR_GAR_2003.11_eng.pdf(accessed on 26 March 2020) 141.HuangC.WangY.LiX.RenL.ZhaoJ.HuY.ZhangL.FanG.XuJ.GuX.et"/>
 <result pre="Health OrganizationConsensus Document on the Epidemiology of Severe Acute Respiratory" exact="Syndrome" post="(SARS)Available online: https://apps.who.int/iris/bitstream/handle/10665/70863/WHO_CDS_CSR_GAR_2003.11_eng.pdf(accessed on 26 March 2020) 141.HuangC.WangY.LiX.RenL.ZhaoJ.HuY.ZhangL.FanG.XuJ.GuX.et al.Clinical"/>
 <result pre="149.RossM.T.GrafhamD.V.CoffeyA.J.SchererS.McLayK.MuznyD.PlatzerM.HowellG.R.BurrowsC.BirdC.P.et al.The DNA sequence of the human X chromosomeNature200543432533710.1038/nature0344015772651 150.SpolaricsZ.PenaG.QinY.DonnellyR.J.LivingstonD.H.Inherent" exact="X-Linked" post="Genetic Variability and Cellular Mosaicism Unique to Females Contribute"/>
 <result pre="Immune ResponseFront. Immunol.20178145510.3389/fimmu.2017.0145529180997 151.LefevreN.CorazzaF.ValsamisJ.DelbaereA.De MaertelaerV.DuchateauJ.CasimirG.The Number of X Chromosomes Influences" exact="Inflammatory" post="Cytokine Production Following Toll-Like Receptor StimulationFront. Immunol.201910105210.3389/fimmu.2019.0105231143188 152.SpolaricsZ.The X-files"/>
 <result pre="Receptor StimulationFront. Immunol.201910105210.3389/fimmu.2019.0105231143188 152.SpolaricsZ.The X-files of inflammation: Cellular mosaicism of" exact="X-linked" post="polymorphic genes and the female advantage in the host"/>
 <result pre="of inflammation: Cellular mosaicism of X-linked polymorphic genes and the" exact="female" post="advantage in the host response to injury and infectionShock20072759760410.1097/SHK.0b013e31802e40bd17505297"/>
 <result pre="time of COVID-19: Time to shut it down?Tob. Control20202924524610.1136/tobaccocontrol-2020-05580732265231 157.SocietyE.R.European" exact="Respiratory" post="SocietyAvailable online: https://www.ersnet.org/covid-19-blog/covid-19--propelled-by-smoking--could-destroy-entire-nations.(accessed on 8 May 2020) 158.LiuW.TaoZ.W.WangL.YuanM.L.LiuK.ZhouL.WeiS.DengY.LiuJ.LiuH.G.et al.Analysis"/>
 <result pre="on 8 May 2020) 158.LiuW.TaoZ.W.WangL.YuanM.L.LiuK.ZhouL.WeiS.DengY.LiuJ.LiuH.G.et al.Analysis of factors associated with" exact="disease" post="outcomes in hospitalized patients with 2019 novel coronavirus diseaseChin."/>
 <result pre="Clin. J. Med.20057291692010.3949/ccjm.72.10.91616231688 160.SimonsD.BrownJ.Covid-19: The role of smoking cessation during" exact="respiratory" post="virus epidemicsBMJ Opin.2020Available online: https://blogs.bmj.com/bmj/2020/03/20/covid-19-the-role-of-smoking-cessation-during-respiratory-virus-epidemics/(accessed on 8 May 2020)"/>
 <result pre="Respir. Viruses2013753153910.1111/j.1750-2659.2012.00411.x22813463 164.AttoB.EapenM.S.SharmaP.FreyU.AmmitA.J.MarkosJ.ChiaC.LarbyJ.HaugG.WeberH.C.et al.New therapeutic targets for the prevention of" exact="infectious" post="acute exacerbations of COPD: Role of epithelial adhesion molecules"/>
 <result pre="Viruses2013753153910.1111/j.1750-2659.2012.00411.x22813463 164.AttoB.EapenM.S.SharmaP.FreyU.AmmitA.J.MarkosJ.ChiaC.LarbyJ.HaugG.WeberH.C.et al.New therapeutic targets for the prevention of infectious" exact="acute" post="exacerbations of COPD: Role of epithelial adhesion molecules and"/>
 <result pre="the prevention of infectious acute exacerbations of COPD: Role of" exact="epithelial" post="adhesion molecules and inflammatory pathwaysClin. Sci.20191331663170310.1042/CS2018100931346069 165.collab: Eurosurveillance Editorial"/>
 <result pre="Eurosurveillance Editorial TeamUpdated rapid risk assessment from ECDC on coronavirus" exact="disease" post="2019 (COVID-19) pandemic: Increased transmission in the EU/EEA and"/>
 <result pre="risk assessment from ECDC on coronavirus disease 2019 (COVID-19) pandemic:" exact="Increased" post="transmission in the EU/EEA and the UKEurosurveillance20202510.2807/1560-7917.ES.2020.25.12.2003261 166.GarufiG.CarbogninL.OrlandiA.TortoraG.BriaE.Smoking habit"/>
 <result pre="EU/EEA and the UKEurosurveillance20202510.2807/1560-7917.ES.2020.25.12.2003261 166.GarufiG.CarbogninL.OrlandiA.TortoraG.BriaE.Smoking habit and hospitalization for severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2)-related pneumonia: The unsolved paradox"/>
 <result pre="and the UKEurosurveillance20202510.2807/1560-7917.ES.2020.25.12.2003261 166.GarufiG.CarbogninL.OrlandiA.TortoraG.BriaE.Smoking habit and hospitalization for severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2)-related pneumonia: The unsolved paradox behind"/>
 <result pre="the UKEurosurveillance20202510.2807/1560-7917.ES.2020.25.12.2003261 166.GarufiG.CarbogninL.OrlandiA.TortoraG.BriaE.Smoking habit and hospitalization for severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2)-related pneumonia: The unsolved paradox behind the"/>
 <result pre="diffusion of COVID-19 and suggested strategy to prevent future accelerated" exact="viral" post="infectivity similar to COVIDSci. Total Environ.202072913847410.1016/j.scitotenv.2020.13847432498152 175.DaughtonC.The international imperative"/>
 <result pre="strategy to prevent future accelerated viral infectivity similar to COVIDSci." exact="Total" post="Environ.202072913847410.1016/j.scitotenv.2020.13847432498152 175.DaughtonC.The international imperative to rapidly and inexpensively monitor"/>
 <result pre="175.DaughtonC.The international imperative to rapidly and inexpensively monitor community-wide Covid-19" exact="infection" post="status and trendsSci. Total Environ.202072613814910.1016/j.scitotenv.2020.13814932315842 176.YangY.WangH.ChenK.ZhouJ.DengS.WangY.Shelter hospital mode: How"/>
 <result pre="rapidly and inexpensively monitor community-wide Covid-19 infection status and trendsSci." exact="Total" post="Environ.202072613814910.1016/j.scitotenv.2020.13814932315842 176.YangY.WangH.ChenK.ZhouJ.DengS.WangY.Shelter hospital mode: How to prevent novel coronavirus"/>
 <result pre="Total Environ.202072613814910.1016/j.scitotenv.2020.13814932315842 176.YangY.WangH.ChenK.ZhouJ.DengS.WangY.Shelter hospital mode: How to prevent novel coronavirus" exact="infection" post="2019 (COVID-19) hospital-acquired infection?Infect. Control Hosp. Epidemiol.202010.1017/ice.2020.9732223769 177.LaiJ.MaS.WangY.CaiZ.HuJ.WeiN.WuJ.DuH.ChenT.LiR.et al.Factors"/>
 <result pre="Mental Health Outcomes Among Health Care Workers Exposed to Coronavirus" exact="Disease" post="2019JAMA Netw. Open20203e20397610.1001/jamanetworkopen.2020.397632202646 178.Dipartimento della Protezione Civile COVID-19 Italiaâ€&quot;Monitoraggio"/>
 <result pre="online: http://opendatadpc.maps.arcgis.com/apps/opsdashboard/index.html#/b0c68bce2cce478eaac82fe38d4138b1(accessed on 7 May 2020) 179.NapoliP.E.NioiM.Global Spread of Coronavirus" exact="Disease" post="2019 and Malaria: An Epidemiological Paradox in the Early"/>
 <result pre="Another co-evolutionary adaptation?Front. Cell Infect. Microbiol.2014412110.3389/fcimb.2014.0012125232536 181.DrissA.HibbertJ.M.WilsonN.O.IqbalS.A.AdamkiewiczT.V.StilesJ.K.Genetic polymorphisms linked to" exact="susceptibility to" post="malariaMalar J.20111027110.1186/1475-2875-10-27121929748 182.ThomasM.R.LipG.Y.Novel Risk Markers and Risk Assessments for"/>
 <result pre="Assessments for Cardiovascular DiseaseCirc. Res.201712013314910.1161/CIRCRESAHA.116.30995528057790 183.GemmatiD.ZeriG.OrioliE.MariR.MoratelliS.ViglianoM.MarchesiniJ.GrossiM.E.PecoraroA.CuneoA.et al.Factor XIII-A dynamics in" exact="acute" post="myocardial infarction: A novel prognostic biomarker?Thromb. Haemost.201511412313210.1160/TH14-11-095225947356 Figure 1"/>
 <result pre="(left) characterized by a balanced ACE1/ACE2 pathway, and during SARS-CoV-2" exact="infection" post="condition (right) in which SARS-CoV-2 mediated suppression of ACE2"/>
 <result pre="ACE2 receptor causes ACE1/ACE2 unbalance responsible for RAS over-activation and" exact="pulmonary" post="shut-down. Figure 3 Hypothesized mechanism of a geneticâ€&quot;environmental interaction"/>
 <result pre="a balanced RAS, normal Ang-II levels (Ang-II â†&quot;â†‘), in the" exact="absence of" post="virus infection. (b) Over-expression of ACE1 receptor as in"/>
 <result pre="RAS, normal Ang-II levels (Ang-II â†&quot;â†‘), in the absence of" exact="virus infection." post="(b) Over-expression of ACE1 receptor as in the presence"/>
 <result pre="rs4340, rs13447447) in combination with ACE2 downregulation due to SARS-CoV-2" exact="infection" post="and/or in the presence of the ACE2 8790 G-allele"/>
 <result pre="rs4340, rs13447447) in combination with ACE2 downregulation due to SARS-CoV-2" exact="infection" post="counteracted by the ACE2 8790 A-allele (i.e., rs2285666), resulting"/>
 <result pre="converting enzyme 2 Xp22.2 AGTR1 (AT1) 336 Angiotensin II receptor" exact="type 1" post="3q24 AGTR2 (AT2) 338 Angiotensin II receptor type 2"/>
 <result pre="receptor type 1 3q24 AGTR2 (AT2) 338 Angiotensin II receptor" exact="type 2" post="Xq23 MAS1 6899 MAS1 proto-oncogene 6q25.3 ABO 79 Î±"/>
</results>
